AbbVie Acquires Gilgamesh Pharmaceuticals' Psychedelic Candidate Bretisilocin
AbbVie has completed the acquisition of Gilgamesh Pharmaceuticals’ investigational compound bretisilocin, a next-generation psychedelic currently in Phase 2 trials for major depressive disorder.